Adial Pharmaceuticals Inc... (ADIL)
The price, the headline numbers and the latest news, in one place.
Adial Pharmaceuticals Inc. (ADIL) Stock Price, Analysis & Data
| Bid | 4.57 |
| Market Cap | 16.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.8M |
| n/a | |
| -17.71 | |
| n/a | |
| -0.83 | |
| P/B (ttm) | -0.43 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 3.08 |
| Volume | 81,569 |
| Avg. Volume (20D) | 420,461 |
| Open | 5.95 |
| Previous Close | 5.90 |
| Day's Range | 5.74 - 6.40 |
| 52-Week Range | 1.31 - 10.75 |
| Analyst | n/a |
| Price Target | 8 (28.82%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The...
Financial Performance
In 2025, Adial Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -7.98M, a decrease of -39.56%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for ADIL stock is "null". The 12-month stock price forecast is 8, which is upside of 28.82% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.29 misses estimates by -0.38, with 71.33% YoY growth.
